Laddar...
Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
Mucopolysaccharidosis type II (MPS II; Hunter syndrome; OMIM 309900) is a rare, multisystemic, progressive lysosomal storage disease caused by deficient activity of the iduronate-2-sulfatase (I2S) enzyme. Accumulation of the glycosaminoglycans dermatan sulfate and heparan sulfate results in a broad...
Sparad:
| I publikationen: | Drug Des Devel Ther |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Dove Medical Press
2017
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5574592/ https://ncbi.nlm.nih.gov/pubmed/28860717 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S139601 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|